These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36928351)

  • 21. Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
    Sershen H; Hashim A; Dunlop DS; Suckow RF; Cooper TB; Javitt DC
    Neurochem Res; 2016 Feb; 41(1-2):398-408. PubMed ID: 26857796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756.
    Howley E; Bestwick M; Fradley R; Harrison H; Leveridge M; Okada K; Fieldhouse C; Farnaby W; Canning H; Sykes AP; Merchant K; Hazel K; Kerr C; Kinsella N; Walsh L; Livermore DG; Hoffman I; Ellery J; Mitchell P; Patel T; Carlton M; Barnes M; Miller DJ
    Neurochem Res; 2017 Nov; 42(11):3279-3288. PubMed ID: 28780732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls.
    Leung S; Croft RJ; O'Neill BV; Nathan PJ
    Psychopharmacology (Berl); 2008 Feb; 196(3):451-60. PubMed ID: 17952411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
    Fone KCF; Watson DJG; Billiras RI; Sicard DI; Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Mol Neurobiol; 2020 May; 57(5):2144-2166. PubMed ID: 31960362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.
    Roser P; Haussleiter IS; Chong HJ; Maier C; Kawohl W; Norra C; Juckel G
    Psychopharmacology (Berl); 2011 Dec; 218(4):611-20. PubMed ID: 21590281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glutamatergic drugs for schizophrenia.
    Tuominen HJ; Tiihonen J; Wahlbeck K
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003730. PubMed ID: 16625590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.
    Strick CA; Li C; Scott L; Harvey B; Hajós M; Steyn SJ; Piotrowski MA; James LC; Downs JT; Rago B; Becker SL; El-Kattan A; Xu Y; Ganong AH; Tingley FD; Ramirez AD; Seymour PA; Guanowsky V; Majchrzak MJ; Fox CB; Schmidt CJ; Duplantier AJ
    Neuropharmacology; 2011; 61(5-6):1001-15. PubMed ID: 21763704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine.
    Hashimoto K; Fujita Y; Horio M; Kunitachi S; Iyo M; Ferraris D; Tsukamoto T
    Biol Psychiatry; 2009 Jun; 65(12):1103-6. PubMed ID: 19217074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. D-serine added to clozapine for the treatment of schizophrenia.
    Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
    Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
    Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia.
    Madeira C; Freitas ME; Vargas-Lopes C; Wolosker H; Panizzutti R
    Schizophr Res; 2008 Apr; 101(1-3):76-83. PubMed ID: 18378121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coumarin derivatives as inhibitors of d-amino acid oxidase and monoamine oxidase.
    Bester E; Petzer A; Petzer JP
    Bioorg Chem; 2022 Jun; 123():105791. PubMed ID: 35413582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment.
    Javitt DC
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():119-141. PubMed ID: 36151052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Test-retest reliability of mismatch negativity and gamma-band auditory steady-state response in patients with schizophrenia.
    Jiao X; Hu Q; Tang Y; Qian Z; Tong S; Wang J; Sun J
    Schizophr Res; 2022 Feb; 240():165-174. PubMed ID: 35030446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
    Kikuchi T
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32751985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time and space profiling of NMDA receptor co-agonist functions.
    Mothet JP; Le Bail M; Billard JM
    J Neurochem; 2015 Oct; 135(2):210-25. PubMed ID: 26088787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contributions of the D-serine pathway to schizophrenia.
    Labrie V; Wong AH; Roder JC
    Neuropharmacology; 2012 Mar; 62(3):1484-503. PubMed ID: 21295046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine.
    Smith SM; Uslaner JM; Yao L; Mullins CM; Surles NO; Huszar SL; McNaughton CH; Pascarella DM; Kandebo M; Hinchliffe RM; Sparey T; Brandon NJ; Jones B; Venkatraman S; Young MB; Sachs N; Jacobson MA; Hutson PH
    J Pharmacol Exp Ther; 2009 Mar; 328(3):921-30. PubMed ID: 19088300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.